Printer Friendly

BOEHRINGER INGELHEIM REACHES CO-PROMOTIONAL AGREEMENT WITH 3M PHARMACEUTICALS FOR ATROVENT (IPRATROPIUM BROMIDE)

 BOEHRINGER INGELHEIM REACHES CO-PROMOTIONAL AGREEMENT WITH
 3M PHARMACEUTICALS FOR ATROVENT (IPRATROPIUM BROMIDE)
 RIDGEFIELD, Conn., Feb. 3 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc., announced that starting today, 3M Pharmaceuticals will co-promote Atrovent(R) (see note below), prescription drug of Boehringer Ingelheim. Under the terms of the agreement, the 3M Pharmaceuticals sales representatives will include the use of Atrovent in chronic obstructive pulmonary disease (COPD) in discussions with healthcare professionals.
 According to the National Center for Health Statistics, COPD is the fourth leading cause of death in the United States. The incidence of COPD has increased from previous NCHS surveys.
 Atrovent was launched in the United States by Boehringer Ingelheim Pharmaceuticals, Inc., in 1987 for the treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema. In 1991, Atrovent sales were in excess of $120 million.
 "Boehringer Ingelheim chose to work with 3M Pharmaceuticals because of their extensive knowledge of the bronchopulmonary marketplace," said John Post, director, market planning, Boehringer Ingelheim Pharmaceuticals, Inc. "The combined efforts of the Boehringer Ingelheim and 3M sales representatives will mean more communication with healthcare professionals about available treatments for COPD."
 Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of the Boehringer Ingelheim Corporation, is an American pharmaceutical company dedicated to the research, development, manufacture and marketing of healthcare products. Boehringer Ingelheim Pharmaceuticals, Inc., has corporate headquarters, R&D, and manufacturing facilities in Ridgefield.
 NOTE: See complete prescribing information for warnings, precautions, and adverse reactions.
 -0- 2/3/92
 /CONTACT: Patricia Morrow of Boehringer Ingelheim, 203-798-5666/ CO: Boehringer Ingelheim Pharmaceuticals, Inc.; 3M Pharmaceuticals ST: Connecticut IN: MTC SU:


SH-GK -- NY017 -- 6025 02/03/92 09:19 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 3, 1992
Words:268
Previous Article:RAMSAY HEALTH CARE, INC. REVISES EARNINGS EXPECTATIONS
Next Article:FOREMOST CORPORATION OF AMERICA DECLARES REGULAR DIVIDEND
Topics:


Related Articles
SPI AND BOEHRINGER INGELHEIM ANNOUNCE EXCLUSIVE AGREEMENT FOR DISTRIBUTION OF SPI'S VIRAZOLE IN GERMANY
CAMBRIDGE NEUROSCIENCE AND BOEHRINGER INGELHEIM ANNOUNCE MAJOR COLLABORATION TO DEVELOP AND COMMERCIALIZE CERESTAT(TM)
ISIS AND BOEHRINGER INGELHEIM SIGN DEFINITIVE AGREEMENT TO FORM CELL ADHESION COLLABORATION; ISIS RECEIVES $28.5 MILLION EQUITY INVESTMENT
Isis Receives $10 Million Milestone Payment from Boehringer Ingelheim for Isis 2302
Snyder Signs Marketing Agreement With Boehringer Ingelheim
Boehringer Ingelheim Signs Deal with Scotia To Develop and Commercialize Foscan(R)
Ariba Signs Boehringer Ingelheim in Major Customer Win
Abbott Laboratories and Boehringer Ingelheim Sign Two Co-Marketing Agreements
Abbott Laboratories and Boehringer Ingelheim Enter U.S. Marketing Collaboration for Key Pharmaceutical Products.
Boehringer Ingelheim Receives FDA Approval for New ATROVENT(R) HFA.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters